Sanjivani Paranteral [SANJIVIN] vs Sun Pharma Advanced [SPARC] Detailed Stock Comparison

Sanjivani Paranteral
BSE
Loading...

Sun Pharma Advanced
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Sanjivani Paranteral wins in 11 metrics, Sun Pharma Advanced wins in 6 metrics, with 0 ties. Sanjivani Paranteral appears stronger overall.
View Metrics Details
Vital Metrics Comparison
Metric | Sanjivani Paranteral | Sun Pharma Advanced | Better |
---|---|---|---|
P/E Ratio (TTM) | 32.24 | -13.92 | Sun Pharma Advanced |
Price-to-Book Ratio | 6.71 | -21.95 | Sun Pharma Advanced |
Debt-to-Equity Ratio | 20.42 | -1.24 | Sun Pharma Advanced |
PEG Ratio | N/A | 0.30 | N/A |
EV/EBITDA | 24.84 | -17.77 | Sun Pharma Advanced |
Profit Margin (TTM) | 11.34% | -53.22% | Sanjivani Paranteral |
Operating Margin (TTM) | 13.88% | -568.05% | Sanjivani Paranteral |
EBITDA Margin (TTM) | 13.88% | N/A | N/A |
Return on Equity | 20.30% | 157.88% | Sun Pharma Advanced |
Return on Assets (TTM) | 10.35% | -102.08% | Sanjivani Paranteral |
Free Cash Flow (TTM) | $-179.46M | $-3.71B | Sanjivani Paranteral |
1-Year Return | -27.22% | -34.43% | Sanjivani Paranteral |
Price-to-Sales Ratio (TTM) | 3.69 | 73.95 | Sanjivani Paranteral |
Enterprise Value | $2.62B | $50.39B | Sun Pharma Advanced |
EV/Revenue Ratio | 3.66 | 78.01 | Sanjivani Paranteral |
Gross Profit Margin (TTM) | 48.33% | -10.68% | Sanjivani Paranteral |
Revenue per Share (TTM) | $61 | $2 | Sanjivani Paranteral |
Earnings per Share (Diluted) | $6.66 | $-9.19 | Sanjivani Paranteral |
Beta (Stock Volatility) | -0.82 | 0.31 | Sanjivani Paranteral |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Sanjivani Paranteral vs Sun Pharma Advanced Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
Stock | 1D | 1W | 1M | 3M | 6M | YTD |
---|---|---|---|---|---|---|
Sanjivani Paranteral | -2.19% | -1.12% | -11.65% | -2.46% | -25.72% | -44.39% |
Sun Pharma Advanced | 0.71% | 1.72% | -7.23% | -10.11% | 14.74% | -27.21% |
Long-term Returns
Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
---|---|---|---|---|---|---|
Sanjivani Paranteral | -27.22% | 333.27% | 2,293.46% | 994.33% | 366.08% | 143.88% |
Sun Pharma Advanced | -34.43% | -37.13% | -23.18% | -60.88% | 58.71% | -49.74% |
Performance & Financial Health Analysis: Sanjivani Paranteral vs Sun Pharma Advanced
Metric | SANJIVIN | SPARC |
---|---|---|
Market Information | ||
Market Cap | ₹2.64B | ₹47.77B |
Market Cap Category | Small cap | Small cap |
10 Day Avg. Volume | 3,528 | 286,237 |
90 Day Avg. Volume | 7,954 | 355,426 |
Last Close | ₹212.30 | ₹146.08 |
52 Week Range | ₹203.10 - ₹396.95 | ₹109.30 - ₹241.00 |
% from 52W High | -46.52% | -39.39% |
All-Time High | ₹396.95 (Dec 30, 2024) | ₹875.00 (Apr 24, 2006) |
% from All-Time High | -46.52% | -83.31% |
Growth Metrics | ||
Quarterly Revenue Growth | 0.09% | -0.43% |
Quarterly Earnings Growth | 0.01% | -0.43% |
Financial Health | ||
Profit Margin (TTM) | 0.11% | -0.53% |
Operating Margin (TTM) | 0.14% | -5.68% |
Return on Equity (TTM) | 0.20% | 1.58% |
Debt to Equity (MRQ) | 20.42 | -1.24 |
Cash & Liquidity | ||
Book Value per Share (MRQ) | ₹31.98 | ₹-6.69 |
Cash per Share (MRQ) | ₹2.04 | ₹0.06 |
Operating Cash Flow (TTM) | ₹35.93M | ₹-3,484,287,000 |
Levered Free Cash Flow (TTM) | ₹80.94M | ₹-3,425,094,000 |
Dividends | ||
Last 12-Month Dividend Yield | N/A | N/A |
Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Sanjivani Paranteral vs Sun Pharma Advanced
Metric | SANJIVIN | SPARC |
---|---|---|
Price Ratios | ||
P/E Ratio (TTM) | 32.24 | -13.92 |
Forward P/E | N/A | 2.65 |
PEG Ratio | N/A | 0.30 |
Price to Sales (TTM) | 3.69 | 73.95 |
Price to Book (MRQ) | 6.71 | -21.95 |
Market Capitalization | ||
Market Capitalization | ₹2.64B | ₹47.77B |
Enterprise Value | ₹2.62B | ₹50.39B |
Enterprise Value Metrics | ||
Enterprise to Revenue | 3.66 | 78.01 |
Enterprise to EBITDA | 24.84 | -17.77 |
Risk & Other Metrics | ||
Beta | -0.82 | 0.31 |
Book Value per Share (MRQ) | ₹31.98 | ₹-6.69 |
Financial Statements Comparison: Sanjivani Paranteral vs Sun Pharma Advanced
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
Metric (MRQ) | SANJIVIN | SPARC |
---|---|---|
Revenue/Sales | ₹178.92M | ₹96.40M |
Cost of Goods Sold | ₹111.14M | ₹106.70M |
Gross Profit | ₹67.78M | ₹-10.30M |
Research & Development | N/A | N/A |
Operating Income (EBIT) | ₹24.84M | ₹-547.60M |
EBITDA | ₹26.83M | ₹-429.40M |
Pre-Tax Income | ₹23.01M | ₹-518.10M |
Income Tax | ₹5.70M | ₹600,000 |
Net Income (Profit) | ₹17.31M | ₹-518.70M |
Balance Sheet & Liquidity Metrics (MRQ)
Metric (MRQ) | SANJIVIN | SPARC |
---|---|---|
Cash & Equivalents | ₹14.85M | ₹19.64M |
Total Current Assets | ₹341.80M | ₹261.97M |
Total Current Liabilities | ₹317.92M | ₹3.74B |
Long-Term Debt | ₹52.89M | ₹1.07B |
Total Shareholders Equity | ₹398.71M | ₹-2.17B |
Retained Earnings | N/A | ₹-23.22B |
Property, Plant & Equipment | ₹205.64M | ₹178.02M |
Cash Flow Statement Comparison (MRQ)
Metric (MRQ) | SANJIVIN | SPARC |
---|---|---|
Operating Cash Flow | N/A | N/A |
Capital Expenditures | N/A | N/A |
Free Cash Flow | N/A | N/A |
Debt Repayment | N/A | N/A |
Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
Metric | SANJIVIN | SPARC |
---|---|---|
Shares Short | N/A | N/A |
Short Ratio | N/A | N/A |
Short % of Float | N/A | N/A |
Average Daily Volume (10 Day) | 3,528 | 286,237 |
Average Daily Volume (90 Day) | 7,954 | 355,426 |
Shares Outstanding | 11.88M | 324.52M |
Float Shares | 5.73M | 91.74M |
% Held by Insiders | 0.55% | 0.73% |
% Held by Institutions | 0.01% | 0.02% |
Dividend Analysis & Yield Comparison: Sanjivani Paranteral vs Sun Pharma Advanced
Metric | SANJIVIN | SPARC |
---|---|---|
Last 12-Month Dividend | N/A | N/A |
Last 12-Month Dividend Yield | N/A | N/A |
3-Year Avg Annual Dividend | N/A | N/A |
3-Year Avg Dividend Yield | N/A | N/A |
3-Year Total Dividends | N/A | N/A |
Ex-Dividend Date | N/A | N/A |